Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Xetra  >  Merck KGaA    MRK   DE0006599905

MERCK KGAA (MRK)
Mes dernières consult.
Most popular
  Report  
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets

Merck KGaA May Withdraw Research from Portugal over Debt-Report

share with twitter share with LinkedIn share with facebook
share via e-mail
0
07/09/2012 | 08:28am CET

German chemical company Merck KGaA (>> Merck KGaA) may withdraw future investments for research projects in Portugal worth tens of millions of euros unless the government hospitals stick to the agreed-upon debt repayments, German daily newspaper Financial Times Deutschland reports Monday.

Merck Portugal's manager Fritz Sacher told the paper the company's research projects are long-term and require mutual trust as a basis. "The Portuguese government's lacking payment habits undermine this trust," he is quoted as saying.

Portuguese government hospitals owe the pharmaceutical industry a total of more than 1.5 billion euros ($1.84 billion) and companies have to wait nearly 550 days on average until invoices are paid, FTD reports.

Some companies, including Roche Holding AG (ROG.VX), have already halted the sale of medications on credit to highly indebted countries like Portugal, Greece, Spain and Italy until outstanding debts are paid, the paper notes, but for many companies such drastic steps are difficult as they carry responsibility for people's wellbeing.

Withdrawing research projects is a way of putting pressure on the government, as Portugal is an attractive location for research investments, FTD says. "The conditions for certain research and human studies are as good as in the U.S., but it's significantly more cost-effective in Portugal," Sacher told the paper.

Newspaper website: http://www.ftd.de

Write to the Frankfurt Bureau at [email protected]

Stocks mentioned in the article : Merck KGaA
Stocks mentioned in the article
ChangeLast1st jan.
MERCK KGAA -0.05% 82.34 Delayed Quote.-8.26%
ROCHE HOLDING LTD. -0.56% 222.05 Delayed Quote.-9.41%
ROCHE HOLDING LTD. -0.95% 192.5 Delayed Quote.-8.72%
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on MERCK KGAA
02/23MERCK : Studies in the Area of Fluorine Chemistry Reported from Merck KGaA (Conv..
AQ
02/22MERCK : MilliporeSigma Strengthens Corporate Responsibility Efforts with Nine Ne..
PU
02/21MERCK : to Invest Additional EUR40 Million in Asia
DJ
02/21MERCK : Darmstadt, Germany Invests Additional $47 Million to Enhance Manufacturi..
PU
02/21BIOLOGICS SAFETY TESTING MARKET : Increase in Biotechnology and Pharmaceuticals ..
AQ
02/20MERCK : and Partners Start EUR20 Million Israel Biotech Fund
DJ
02/20MERCK : The Life Science Business of Merck KGaA, Darmstadt, Germany to Receive T..
PU
02/20MERCK : Darmstadt, Germany, and Three Partners Start ExploreBio, a € 20 million ..
PU
02/19Reckitt shares sink on missed profit, vague outlook
RE
02/19GLYCOBIOLOGY MARKET 2017 TO 2025 BY : Agilent Technologies Inc, Waters Corporat..
AQ
More news
News from SeekingAlpha
02/22Merck KGaA and Pfizer's Bavencio OK'd in Canada for rare type of skin cancer 
02/21Merck KGaA to beef up manufacturing and distribution in Asia 
02/203 THINGS IN BIOTECH YOU SHOULD LEARN : February 19, 2018 
02/13BioLife inks supply agreement with MilliporeSigma; shares up 4% 
02/02Nestle backs away from Merck KGaA's consumer unit 
Financials (€)
Sales 2017 15 336 M
EBIT 2017 3 358 M
Net income 2017 1 697 M
Debt 2017 9 767 M
Yield 2017 1,55%
P/E ratio 2017 17,81
P/E ratio 2018 18,73
EV / Sales 2017 1,33x
EV / Sales 2018 1,19x
Capitalization 10 642 M
Chart MERCK KGAA
Duration : Period :
Merck KGaA Technical Analysis Chart | MRK | DE0006599905 | 4-Traders
Technical analysis trends MERCK KGAA
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 27
Average target price 107 €
Spread / Average Target 30%
EPS Revisions
Managers
NameTitle
Wolfgang Heinz Büchele Chairman-Supervisory Board
Marcus Kuhnert Chief Financial Officer
Crocifissa Attardo Member-Supervisory Board
Mechthild Auge Member-Supervisory Board
Michael Fletterich Vice Chairman-Supervisory Board
Sector and Competitors
1st jan.Capitalization (M$)
MERCK KGAA-8.26%13 083
ABBVIE21.56%188 235
KYOWA HAKKO KIRIN CO LTD2.75%12 193
JAZZ PHARMACEUTICALS PLC7.26%8 716
ZHANGZHOU PIENTZEHUANG PHARMACEUTICL LTD16.12%6 992
CONVATEC GROUP2.87%5 763